Casdin Group Files Schedule 13D/A Reporting 6.7M BLFS Shares (14%)

Rhea-AI Filing Summary

Casdin-related entities reported a 14.0% stake in BioLife Solutions (BLFS), owning 6,707,165 common shares based on 47,905,265 shares outstanding as of July 31, 2025. The shares are held by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin, who together share voting and dispositive power over the reported shares. The Reporting Persons state the shares were purchased for investment using the Fund's working capital and that no borrowed funds were used other than ordinary working capital borrowings. They state no current plans to pursue corporate control changes but reserve the right to recommend actions or cooperate with others to maximize shareholder value.

Positive

• Material 14.0% stake disclosed — Reporting Persons beneficially own 6,707,165 shares representing 14.0% of outstanding shares, a significant, material stake.
• Purchase funded from fund working capital — The shares were acquired using the Fund's working capital with no borrowed funds used for the purchases (other than ordinary working capital borrowings).
• Clear disclosure of voting/dispositive power — The filing states shared voting and dispositive power across Casdin entities, clarifying control structure.

Negative

• None.

Insights

Securities Analyst

TL;DR: Casdin group holds a significant 14.0% position in BLFS, signaling meaningful shareholder influence while claiming an investment purpose.

The filing discloses a concentrated stake equal to 14.0% of BioLife Solutions' outstanding common stock, which is material for investors and may warrant monitoring for future engagement or activism despite the Reporting Persons' present statement of an investment purpose only. Shared voting and dispositive power across Casdin entities implies coordinated control over disposition and voting decisions. The disclosure that purchases were made from fund working capital and without leverage (other than ordinary working capital borrowings) reduces immediate balance-sheet risk related to the acquisition. The filing also expressly reserves rights to pursue changes or collaborate with other shareholders later, which keeps strategic options open and could become material if exercised.

Corporate Governance Expert

TL;DR: A 14% stake is large enough to influence governance discussions; current posture is passive but retains potential for future activism.

The reporting group disclaims present plans to change board composition, capital structure, or other governance matters, which is a common framing to avoid signaling near-term takeover intentions. However, by retaining the right to recommend actions and to act in concert with other shareholders, the Reporting Persons preserve the ability to press governance or strategic initiatives later. For boards and management, the filing should trigger consideration of shareholder engagement and preparedness for potential proposals, given the stake size and coordinated ownership across related entities.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 5)

BioLife Solutions, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

09062W204

(CUSIP Number)

Eli Casdin
Casdin Capital, LLC, 1350 Avenue of the Americas, Suite 2405
New York, NY, 10019
212-897-5438

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

08/15/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Casdin Capital, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,707,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,707,165.00

11

Aggregate amount beneficially owned by each reporting person

6,707,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.0 %

14

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Casdin Partners Master Fund, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,707,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,707,165.00

11

Aggregate amount beneficially owned by each reporting person

6,707,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Casdin Partners GP, LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,707,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,707,165.00

11

Aggregate amount beneficially owned by each reporting person

6,707,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.0 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 09062W204

1

Name of reporting person

Eli Casdin

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,707,165.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,707,165.00

11

Aggregate amount beneficially owned by each reporting person

6,707,165.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

14.0 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BioLife Solutions, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3303 Monte Villa Parkway, Bothell, WASHINGTON , 98021.
Item 1 Comment: The name of the issuer is BioLife Solutions, Inc., a Delaware corporation (the "Issuer"). The address of the Issuer's principal executive offices is 3303 Monte Villa Parkway, Suite 310, Bothell, Washington, 98021. This Schedule 13D amendment relates to the Issuer's Common Stock, par value $0.001 per share (the "Shares").
Item 2.	Identity and Background
(a)	(a), (f) This Schedule 13D is being filed jointly by Casdin Capital, LLC, a Delaware limited liability company ("Casdin"), Casdin Partners Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), Casdin Partners GP, LLC, a Delaware limited liability company (the "GP") and Eli Casdin, a United States citizen (collectively, the "Reporting Persons").
(b)	The principal business address for each of the Reporting Persons is 1350 Avenue of the Americas, Suite 2600, New York, New York 10019.
(c)	Eli Casdin is the managing member of Casdin and the GP. The principal business of Casdin is serving as an investment adviser to its clients. The principal business of the GP is serving as the general partner to certain private funds. Casdin is the investment manager to the Fund and the GP is the general partner of the Fund. The principal business of the Fund is purchasing, holding and selling securities for investment purposes.
(d)	(d), (e) During the last five years, none of the Reporting Persons has been (a) convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (b) a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. The Reporting Persons disclaim membership in a group.
Item 3.	Source and Amount of Funds or Other Consideration
	The funds for the purchase of the Shares by the Fund came from the working capital of the Fund, over which the Reporting Persons, through their roles described above in Item 2(c), exercise investment discretion. No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.
Item 4.	Purpose of Transaction
	he Reporting Persons have acquired their Shares of the Issuer for investment. The Reporting Persons have no plans or proposals as of the date of this filing which, other than as expressly set forth below, would relate to or would result in: (a) any extraordinary corporate transaction involving the Issuer; (b) any change in the present Board of Directors or management of the Issuer; (c) any material change in the present capitalization or dividend policy of the Issuer; (d) any material change in the operating policies or corporate structure of the Issuer; (e) any change in the Issuer's charter or by-laws; (f) the Shares of the Issuer ceasing to be listed from a national securities exchange or to ceasing to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; or (g) causing the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Exchange Act of 1934. The Reporting Persons, however, reserve the right, at a later date, to effect one or more of such changes and may dispose of or enter into other transactions in the shares they may be deemed to beneficially own. The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value. The Reporting Persons further reserve the right to act in concert with any other shareholders of the Issuer, or other persons, for a common purpose should it determine to do so, and/or to recommend courses of action to management and the shareholders of the Issuer.
Item 5.	Interest in Securities of the Issuer
(a)	(a) - (e) As of the date hereof, Casdin, the Fund, the GP and Eli Casdin may be deemed to be the beneficial owners of 6,707,165 Shares, constituting 14.0% of the Shares based upon 47,905,265* Shares outstanding. Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 6,707,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 6,707,165 Shares. The Fund has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 6,707,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 6,707,165 Shares. The GP has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 6,707,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 6,707,165 Shares. Eli Casdin has the sole power to vote or direct the vote of 0 Shares; has the shared power to vote or direct the vote of 6,707,165 Shares; has the sole power to dispose or direct the disposition of 0 Shares; and has the shared power to dispose or direct the disposition of 6,707,165 Shares. The transactions by the Reporting Persons in the Shares are set forth in Exhibit B. *This outstanding Shares figure reflects the number of outstanding Shares as of July 31, 2025.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not Applicable.
Item 7.	Material to be Filed as Exhibits.
	Exhibit A: Joint Filing Agreement Exhibit B: Schedule of Transactions in Shares

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Casdin Capital, LLC

Signature:	By: /s/ Eli Casdin*
Name/Title:	Eli Casdin, Managing Member
Date:	08/21/2025

Casdin Partners Master Fund, L.P.

Signature:	By: /s/ Eli Casdin*
Name/Title:	Eli Casdin, Managing Member of its General Partner
Date:	08/21/2025

Casdin Partners GP, LLC

Signature:	By: /s/ Eli Casdin*
Name/Title:	Eli Casdin, Managing Member
Date:	08/21/2025

Eli Casdin

Signature:	By: /s/ Eli Casdin*
Name/Title:	Eli Casdin
Date:	08/21/2025

Comments accompanying signature:

* This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose. Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

FAQ

How many BLFS shares does Casdin beneficially own?

The Reporting Persons beneficially own 6,707,165 shares, representing 14.0% of BLFS outstanding shares based on 47,905,265 shares outstanding as of July 31, 2025.

Who are the reporting parties in the Schedule 13D/A for BLFS?

The filing is by Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC and Eli Casdin (collectively, the Reporting Persons).

What was the stated purpose for acquiring BLFS shares?

The Reporting Persons state the shares were acquired for investment and currently have no plans to effect extraordinary corporate transactions, management changes, or material changes to capitalization, but reserve the right to act later.

Were borrowed funds used to purchase the BLFS shares?

No borrowed funds were used to purchase the Shares, other than borrowed funds used for working capital purposes in the ordinary course of business.

Does the filing indicate coordination among the Casdin entities?

Yes. The filing shows shared voting and dispositive power over the reported shares among the Casdin entities, indicating coordinated control.